The vasomotor menopausal symptoms (VMS) treatment market size has grown strongly in recent years. It will grow from $17.86 billion in 2024 to $19.19 billion in 2025 at a compound annual growth rate (CAGR) of 7.5%. The growth in the historic period can be attributed to hormone replacement therapy (hrt), menopause awareness, pharmaceutical developments, consumer demand.
The vasomotor menopausal symptoms (VMS) treatment market size is expected to see strong growth in the next few years. It will grow to $24.81 billion in 2029 at a compound annual growth rate (CAGR) of 6.6%. The growth in the forecast period can be attributed to personalized medicine, non-hormonal innovations, nutritional and dietary interventions, telemedicine and digital health. Major trends in the forecast period include natural and alternative approaches, botanical and herbal remedies, menopause support groups, cognitive behavioral therapy (cbt).
The expansion of the vasomotor menopausal symptoms treatment market is fueled by the increasing menopausal population. Menopause, a natural biological phase signifying the end of a woman's reproductive years, typically occurs between the ages of 45 and 55, with an average age of around 51. The growing number of menopausal women worldwide seeking treatment for symptoms like hot flashes and vaginal dryness is a key factor propelling the growth of treatments for vasomotor menopausal symptoms (VMS). For example, data from the Cuyuna Regional Medical Center, a U.S.-based organization, indicates that due to increased life expectancy, an estimated 1.1 billion women will reach menopause by 2025. Additionally, the menopausal population is projected to grow by 1.6% annually until 2060. Hence, the expanding menopausal demographic is a driving force behind the vasomotor menopausal symptoms treatment market's growth.
Government initiatives focused on women's health during menopause are set to drive the growth of the vasomotor menopausal symptoms treatment market. These initiatives encompass funding for innovative research on various aspects of the menopausal transition, disease prevention, and pharmacological, clinical, and epidemiological investigations. Such efforts are part of broader women's health initiatives that address a wide range of concerns. As an illustration, the Government of New South Wales, an Australia-based government agency, has allocated $40.3 million over four years (from 2022-2023 to 2025-2026) to establish up to 16 new programs aimed at assisting women experiencing severe menopausal symptoms. Therefore, these government initiatives focusing on women's health during menopause are propelling the growth of the market for vasomotor menopausal symptoms treatment.
Prominent companies engaged in the vasomotor menopausal symptoms treatment market are prioritizing the development of products like Veozah and securing approvals to offer new treatment alternatives that address unmet medical requirements for patients. The approval of novel drugs for menopausal symptom management presents advantages in terms of improved efficacy and safety compared to existing treatments. For example, in May 2023, Astellas Pharma Inc., a Japan-based pharmaceutical company, received FDA approval for Veozah (fezolinetant) 45 mg, designed to be taken once daily, for the treatment of menopausal vasomotor symptoms (VMS), spanning from mild to severe. Veozah is the first nonhormonal neurokinin 3 (NK3) receptor antagonist authorized for managing menopausal-related VMS. This hormone-free option functions by blocking a neural pathway involved in regulating these symptoms. Veozah provides an alternative treatment choice, particularly for women experiencing such symptoms who either cannot or prefer not to use hormone therapy. The approval of Veozah underscores its potential as a novel drug for addressing menopausal symptoms.
In March 2022, Amyris Inc., a U.S.-based biotechnology firm, acquired MenoLabs LLC for $35.4 million. This acquisition enables Amyris to broaden its presence in the women's health market, gain access to new technologies and capabilities, and acquire a dedicated customer base. MenoLabs LLC, a U.S.-based women's health and technology company, specializes in the development of dietary supplements designed to alleviate menopause symptoms in women.
Major companies operating in the vasomotor menopausal symptoms (vms) treatment market are Pfizer Inc., Abbvie Inc., Novartis AG, Ausio Pharmaceuticals LLC, Teva Pharmaceutical Industries Ltd., Mylan N.V., Sun Pharmaceutical Industries Ltd., Aurobindo Pharma Limited, Kyowa Kirin Co. Ltd., Dr. Reddy's Laboratories Ltd., Alembic Pharmaceuticals Limited Inc., Apotex Inc., Hikma Pharmaceutical PLC, Endo Pharmaceuticals PLC, Amneal Pharmaceuticals LLC, Mundipharma International Ltd., Lupin Limited, Glenmark Pharmaceuticals Ltd., Hisamitsu Pharmaceutical Co. Inc., Zhejiang Huahai Pharmaceutical Co. Ltd., Emcure Pharmaceuticals Limited, Wockhardt Pvt. Ltd., QuatRx Pharmaceuticals Company, Bionovo Inc., Mithra Pharmaceuticals SA, EndoCeutics Inc., Zydus Group, Edgemont Pharmaceuticals LLC, MenoGeniX Inc., Agile Therapeutics Inc.
North America was the largest region in the vasomotor menopausal symptoms (VMS) treatment market in 2024. The regions covered in vasomotor menopausal symptoms (VMS) treatment report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa. The countries covered in the vasomotor menopausal symptoms (VMS) treatment market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
The vasomotor menopausal symptoms (VMS) treatment market consists of revenues earned by entities by providing services such as cognitive-behavioral therapy, acupuncture, lifestyle modifications, herbal and vitamin supplements and complementary and alternative therapies. The market value includes the value of related goods sold by the service provider or included within the service offering. The vasomotor menopausal symptoms (VMS) treatment market also includes sales of natural supplements, cooling products, vaginal estrogen products, stress-reduction products, sleep aids and dietary supplements. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
Vasomotor menopausal symptoms (VMS) treatment involves medical interventions and therapies aimed at alleviating or managing the range of symptoms associated with menopause. These symptoms, experienced by women during menopause, include hot flashes and night sweats. The treatment approach focuses on rebalancing hormone levels in the body and modifying neurotransmitters in the brain.
The primary categories of medications used in vasomotor menopausal symptoms (VMS) treatment include antidepressants like fluoxetine, paroxetine, and sertraline, hormone therapy, anticonvulsants such as phenytoin and phenobarbital, and others. Antidepressants constitute a class of drugs primarily prescribed to address depression and certain other mental health conditions. These medications are available through various distribution channels, including hospital pharmacies, online pharmacies, and retail pharmacies, catering to different end-users such as hospitals, specialty clinics, and homecare settings.
The vasomotor menopausal symptoms (VMS) treatment market research report is one of a series of new reports that provides vasomotor menopausal symptoms (VMS) treatment market statistics, including vasomotor menopausal symptoms (VMS) treatment industry global market size, regional shares, competitors with a vasomotor menopausal symptoms (VMS) treatment market share, detailed vasomotor menopausal symptoms (VMS) treatment market segments, market trends and opportunities and any further data you may need to thrive in the vasomotor menopausal symptoms (VMS) treatment industry. This vasomotor menopausal symptoms (VMS) treatment market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
This product will be delivered within 3-5 business days.
Table of Contents
Executive Summary
Vasomotor Menopausal Symptoms (VMS) Treatment Global Market Report 2025 provides strategists, marketers and senior management with the critical information they need to assess the market.This report focuses on vasomotor menopausal symptoms (vms) treatment market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Reasons to Purchase:
- Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
- Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
- Create regional and country strategies on the basis of local data and analysis.
- Identify growth segments for investment.
- Outperform competitors using forecast data and the drivers and trends shaping the market.
- Understand customers based on the latest market shares.
- Benchmark performance against key competitors.
- Suitable for supporting your internal and external presentations with reliable high quality data and analysis
- Report will be updated with the latest data and delivered to you along with an Excel data sheet for easy data extraction and analysis.
- All data from the report will also be delivered in an excel dashboard format.
Description
Where is the largest and fastest growing market for vasomotor menopausal symptoms (vms) treatment? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The vasomotor menopausal symptoms (vms) treatment market global report answers all these questions and many more.The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market’s historic and forecast market growth by geography.
- The market characteristics section of the report defines and explains the market.
- The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
- The forecasts are made after considering the major factors currently impacting the market. These include:
- The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.
- Market segmentations break down the market into sub markets.
- The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
- The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
- The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.
Scope
Markets Covered:
1) By Drug Class: Antidepressants; Fluoxetine; Paroxetine; Sertraline; Hormone Therapy; Anticonvulsant; Phenytoin; Phenobarbital; Other Drug Classes2) By Distribution Channel: Hospital Pharmacy; Retail Pharmacy; Online Pharmacy; Other Distribution Channels
3) By End-User: Hospitals; Specialty Clinics; Homecare; Other End-Users
Subsegments:
1) By Antidepressants: SSRIs (Selective Serotonin Reuptake Inhibitors); SNRIs (Serotonin-Norepinephrine Reuptake Inhibitors); TCAs (Tricyclic Antidepressants); MAOIs (Monoamine Oxidase Inhibitors); Atypical Antidepressants2) By Fluoxetine: Depression; Obsessive-Compulsive Disorder (OCD); Panic Disorder; Generalized Anxiety Disorder (GAD); Post-Traumatic Stress Disorder (PTSD); Social Anxiety Disorder; Premenstrual Dysphoric Disorder (PMDD)
3) By Paroxetine: Depression; Obsessive-Compulsive Disorder (OCD); Panic Disorder; Generalized Anxiety Disorder (GAD); Post-Traumatic Stress Disorder (PTSD); Social Anxiety Disorder; Premenstrual Dysphoric Disorder (PMDD)
4) Sertraline: Depression; Obsessive-Compulsive Disorder (OCD); Panic Disorder; Post-Traumatic Stress Disorder (PTSD); Social Anxiety Disorder; Premenstrual Dysphoric Disorder (PMDD)
5) Hormone Therapy: Estrogen Replacement Therapy (ERT); Progestin Therapy; Combined Hormonal Therapy (CHT); Testosterone Replacement Therapy (TRT)
6) Anticonvulsant: Hydantoins; Barbiturates; Benzodiazepines; Valproates; Succinimides; Carboxylic Acid Derivatives
7) Phenytoin: Hydantoins
8) Phenobarbital: Barbiturates
9) Other Drug Classes: Antibiotics; Analgesics; Antidiabetics; Antihypertensives; Anticoagulants; Immunosuppressants; Antipsychotics; Antihistamines
Key Companies Mentioned: Pfizer Inc.; Abbvie Inc.; Novartis AG; Ausio Pharmaceuticals LLC; Teva Pharmaceutical Industries Ltd.
Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
Time Series: Five years historic and ten years forecast.
Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita.
Data Segmentation: Country and regional historic and forecast data, market share of competitors, market segments.
Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
Delivery Format: PDF, Word and Excel Data Dashboard.
Companies Mentioned
Some of the major companies featured in this Vasomotor Menopausal Symptoms (VMS) Treatment market report include:- Pfizer Inc.
- Abbvie Inc.
- Novartis AG
- Ausio Pharmaceuticals LLC
- Teva Pharmaceutical Industries Ltd.
- Mylan N.V.
- Sun Pharmaceutical Industries Ltd.
- Aurobindo Pharma Limited
- Kyowa Kirin Co. Ltd.
- Dr. Reddy's Laboratories Ltd.
- Alembic Pharmaceuticals Limited Inc.
- Apotex Inc.
- Hikma Pharmaceutical plc
- Endo Pharmaceuticals plc
- Amneal Pharmaceuticals LLC
- Mundipharma International Ltd.
- Lupin Limited
- Glenmark Pharmaceuticals Ltd.
- Hisamitsu Pharmaceutical Co. Inc.
- Zhejiang Huahai Pharmaceutical Co. Ltd.
- Emcure Pharmaceuticals Limited
- Wockhardt Pvt. Ltd.
- QuatRx Pharmaceuticals Company
- Bionovo Inc.
- Mithra Pharmaceuticals SA
- EndoCeutics Inc.
- Zydus Group
- Edgemont Pharmaceuticals LLC
- MenoGeniX Inc.
- Agile Therapeutics Inc.
Table Information
Report Attribute | Details |
---|---|
No. of Pages | 200 |
Published | March 2025 |
Forecast Period | 2025 - 2029 |
Estimated Market Value ( USD | $ 19.19 Billion |
Forecasted Market Value ( USD | $ 24.81 Billion |
Compound Annual Growth Rate | 6.6% |
Regions Covered | Global |
No. of Companies Mentioned | 30 |